Do patients with prediabetes managed with metformin achieve better glycaemic control? A national study using primary care medical records
Authors:
- Mingyue ZhengMZMingyue Zheng
- SoumyaSOSoumya
- Mumtaz BegumMBMumtaz Begum
Open Access
- 8 July 2023
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 40 (9) , e15170
Abstract
Aims: To estimate the effectiveness of metformin on glycaemic parameters among participants with incident prediabetes attending Australian general practices.Methods: This retrospective cohort study used electronic health records of regular participants (3+ visits in two consecutive years) attending 383 Australian general practices (MedicineInsight). Participants with ‘incident’ prediabetes (newly recorded diagnosis between 2012 and 2017) and their glycaemic parameters (haemoglobin A1c [HbA1c] or fasting blood glucose [FBG]) at 6‐, 12‐, and 18–24 months post diagnosis (unexposed) or post‐management with metformin (treatment) were identified from the database. We estimated the average treatment effect (ATE) of metformin management on glycaemic parameters using both linear regression and augmented inverse probability weighting.Results: Of the 4770 investigated participants with ‘incident’ prediabetes, 10.2% were managed with metformin. Participants on metformin had higher HbA1c levels at the baseline than those unexposed (mean 45 mmol/mol [6.2%] and 41 mmol/mol [5.9%], respectively), but no differences were observed at 6–12 months (mmol/mol ATE 0.0, 95% CI −0.4; 0.7) or 12–18 months (ATE −0.3, 95% CI −1.2; 0.3). However, participants on metformin had lower mean HbA1c mmol/mol at 18–24 months (ATE −1.1, 95% CI −2.0; 0.1) than those unexposed. Consistent results were observed for FBG (ATE at 6–12 months −0.14 [95% CI −0.25; −0.04], 12–18 months 0.02 [95% CI −0.08; 0.13] and 18–24 months −0.07 [95% CI −0.25; 0.12]).Conclusion: The higher HbA1c and FBG baseline levels among participants with ‘incident’ prediabetes managed with metformin improved after 6–12 months of starting pharmacological management, and the effect persisted for up to 24 months. Management with metformin could prevent further deterioration of glycaemic levels.Keywords
This publication has 28 references indexed in Scilit:
- Impact of the National Health Service Health Check on cardiovascular disease risk: a difference-in-differences matching analysisCanadian Medical Association Journal, 2016
- Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort studyThe Lancet Diabetes & Endocrinology, 2016
- Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes StudyThe Lancet Diabetes & Endocrinology, 2015
- Therapeutic Use of Metformin in Prediabetes and Diabetes PreventionDrugs, 2015
- Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline RecommendationsDiabetes Care, 2014
- Doubly Robust Estimation of Causal EffectsAmerican Journal of Epidemiology, 2011
- Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetesBMJ, 2010
- Multiple imputation for missing data in epidemiological and clinical research: potential and pitfallsBMJ, 2009
- Using the outcome for imputation of missing predictor values was preferredJournal of Clinical Epidemiology, 2006
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminNew England Journal of Medicine, 2002